Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virus.

Journal Article (Journal Article;Multicenter Study)

OBJECTIVE: We tested the hypothesis that concentrated formula (CF) begun within the first 2 weeks of life increases growth in infants born to human immunodeficiency virus (HIV)-infected mothers. MATERIALS AND METHODS: HIV-exposed infants from the United States, the Bahamas, and Brazil were randomized in a double-blind, controlled trial to receive either a CF (87 kcal/100 mL [26 kcal/oz]) or a standard formula (SF; 67 kcal/100 mL [20 kcal/oz]) for 8 weeks. This article presents results for infants who were not determined to be HIV infected based on testing at 4 weeks. Primary outcomes were safety, tolerability, and growth in weight and length. RESULTS: Two thousand ninety-seven infants were enrolled, of whom 1998 were uninfected and had study formula dispensed. At weeks 4 and 8, uninfected infants receiving CF showed higher energy intake than those who were receiving SF (P < 0.001). By week 8, uninfected infants assigned to CF weighed more than infants receiving SF. There were no consistent differences in measures of tolerability, and rates of discontinuation or perceived formula intolerance were similar between treatment groups. CONCLUSIONS: A CF is well tolerated and results in increased weight gain compared with SF. Until the HIV status of an infant is reliably determined, early introduction of a CF in HIV-exposed children may have beneficial effects on growth. The role of early nutritional intervention remains to be determined for individuals living in countries with endemic malnutrition for whom formula feeding is a viable option.

Full Text

Duke Authors

Cited Authors

  • Winter, HS; Oleske, JM; Hughes, MD; McKinney, RE; Elgie, C; Powell, C; Purdue, L; Puga, AM; Jimenez, E; Scott, GB; Cruz, MLS; Moye, J; Pediatric AIDS Clinical Trials Group Protocol 247 Study Team,

Published Date

  • August 2009

Published In

Volume / Issue

  • 49 / 2

Start / End Page

  • 222 - 232

PubMed ID

  • 19543114

Pubmed Central ID

  • PMC3934421

Electronic International Standard Serial Number (EISSN)

  • 1536-4801

Digital Object Identifier (DOI)

  • 10.1097/MPG.0b013e3181928937


  • eng

Conference Location

  • United States